Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907598 | 0.86 | FFAR1 (0.35) | FFAR1CYP4F2CYP4A11ACLYLMNA | |
| SCHEMBL27789372 | 0.79 | ALOX15 (0.43) | CYP4F2CYP4A11LMNA | |
| SCHEMBL2723041 | 0.76 | TRPV4 (0.39) | FFAR1 | |
| SCHEMBL6907595 | 0.76 | CYP4F2 (0.37) | FFAR1CYP4F2CYP4A11LMNAMAPK1 | |
| SCHEMBL3052660 | 0.75 | HDAC1 (0.42) | HDAC1HDAC6LMNAHTTRAB9A | |
| SCHEMBL2729260 | 0.75 | MEN1 (0.39) | LMNAHTT | |
| SCHEMBL27962302 | 0.75 | PKM (0.45) | MAPK1 | |
| SCHEMBL28784596 | 0.74 | CYP4F2 (0.33) | CYP4F2CYP4A11LMNAHTTRAB9A | |
| SCHEMBL4611447 | 0.72 | HDAC1 (0.42) | HDAC1HDAC6CYP4F2CYP4A11LMNA | |
| SCHEMBL7211056 | 0.72 | KDM4E (0.40) | HDAC1HDAC6CYP4F2CYP4A11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2013-10-03 | — | — | US | disclosed |
| US-8314147-B2 | Benzamide derivatives as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2012-11-20 | — | — | US | disclosed |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | GLAXO GROUP LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2101751-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-09-23 | — | — | EP | disclosed |
| US-20080167377-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| WO-2008071736-A1 | BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167377-A1 | Novel compounds | F12, C1R, MRGPRX1 | HDAC1 1367/4885HDAC6 935/4885FFAR1 1852/4885 |
| US-20100022650-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | HDAC1 777/4885HDAC6 1438/4885FFAR1 110/4885 |
| US-20130261185-A1 | Benzamide Derivatives As EP4 Receptor Agonists | PTGER4, PTGER1, PTGER3 | HDAC1 777/4885HDAC6 1438/4885FFAR1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.